Dataset Information


FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity.

ABSTRACT: Cancer stem-like cells (CSC) contribute to therapy resistance and recurrence. Focal adhesion kinase (FAK) has a role in CSC regulation. We determined the effect of FAK inhibition on breast CSC activity alone and in combination with adjuvant therapies. FAK inhibition reduced CSC activity and self-renewal across all molecular subtypes in primary human breast cancer samples. Combined FAK and paclitaxel reduced self-renewal in triple negative cell lines. An invasive breast cancer cohort confirmed high FAK expression correlated with increased risk of recurrence and reduced survival. Co-expression of FAK and CSC markers was associated with the poorest prognosis, identifying a high-risk patient population. Combined FAK and paclitaxel treatment reduced tumour size, Ki67, ex-vivo mammospheres and ALDH+ expression in two triple negative patient derived Xenograft (PDX) models. Combined treatment reduced tumour initiation in a limiting dilution re-implantation PDX model. Combined FAK inhibition with adjuvant therapy has the potential to improve breast cancer survival.

PROVIDER: S-EPMC8163772 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC4791238 | BioStudies
| S-EPMC5805730 | BioStudies
| S-EPMC4887598 | BioStudies
| S-EPMC4431480 | BioStudies
2019-07-01 | GSE129097 | GEO
2019-07-01 | GSE129098 | GEO
| S-EPMC7734155 | BioStudies
| S-EPMC2810075 | BioStudies
| S-EPMC6347692 | BioStudies
| S-EPMC7791049 | BioStudies